Acenocoumarol
Anticoagulant
- X
administration
- B01AA07 (WHO)
- UK: POM (Prescription only)
- (RS)-4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
- 152-72-7 Y
- 9052
- DB01418 Y
- 10443441 Y
- I6WP63U32H
- D07064 Y
- CHEBI:53766 Y
- ChEMBL397420 Y
- DTXSID2022541
- Interactive image
- CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(OC3=CC=CC=C3C2=O)O
- InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3 Y
- Key:VABCILAOYCMVPS-UHFFFAOYSA-N Y
Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is generic, so is marketed under many brand names worldwide.[1]
References
- ^ "International listings for acenocoumarol". Drugs.com.
Further reading
- Cesar JM, García-Avello A, Navarro JL, Herraez MV (October 2004). "Aging and oral anticoagulant therapy using acenocoumarol". Blood Coagulation & Fibrinolysis. 15 (8): 673–676. doi:10.1097/00001721-200412000-00007. PMID 15613922. S2CID 19214006.
- Lengyel M (December 2004). "[Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]". Orvosi Hetilap. 145 (52): 2619–2621. PMID 15724697.
- Ufer M (2005). "Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol". Clinical Pharmacokinetics. 44 (12): 1227–1246. doi:10.2165/00003088-200544120-00003. PMID 16372822. S2CID 42970169.
- Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J (April 2006). "The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients". British Journal of Haematology. 133 (2): 183–187. doi:10.1111/j.1365-2141.2006.06007.x. hdl:10171/21989. PMID 16611310. S2CID 369821.
External links
- Diseases Database (DDB): 29202
- v
- t
- e
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) |
| ||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e